Pneumococcal Conjugate Vaccine for Adults: A New Paradigm

Advances in Pneumococcal Disease Prevention: 13-Valent Pneumococcal Conjugate Vaccine for Infants and Children

(2011) P. R. Paradiso   CLINICAL INFECTIOUS DISEASES

Hyporesponsiveness Following Booster Immunization With Bacterial Polysaccharides Is Caused by Apoptosis of Memory B Cells

(2011) Siggeir F. Brynjolfsson et al.   JOURNAL OF INFECTIOUS DISEASES

Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

(2011) Elizabeth Miller et al.   VACCINE

Determining the Optimal Pneumococcal Vaccination Strategy for Adults

(2010) Mark L. Metersky et al.   CHEST

Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe

(2010) Ralf R Reinert et al.   Expert Review of Vaccines

A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults

(2010) Neil French et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical and economic burden of pneumococcal disease in older US adults

(2010) Derek Weycker et al.   VACCINE

Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine

(2009) Tamara Pilishvili et al.   JOURNAL OF INFECTIOUS DISEASES